The approach of active surveillance, which is increasingly common with prostate cancer patients, is becoming more frequently discussed as an option for selected patients with other types of slow-growing, early-stage cancers also. The author, who himself opted for active surveillance, reviews reasons why watchful waiting may be becoming more often chosen – primarily due to therapy side effects and cost. Considerations for insurers in framing their positions about active surveillance are covered.
Source: Kirkner, R.M. (2016, Oct.). Don’t just do something, stand there: How more types of cancer are lending themselves to active surveillance. Managed Care, 25(10), 25-28. Click here: http://www.managedcaremag.com/archives/2016/10/don-t-just-do-something-stand-there-how-more-types-cancer-are-lending-themselves Posted by AHA Resource Center (312) 422.2050, firstname.lastname@example.org